IN
INTI.US Inhibitor Therapeutics Inc
- Market cap
- USD 14.0M
- P/E
- -
- P/B
- 9.89x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is INTI.US undervalued?
Graham numberThe Graham number of Inhibitor Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Inhibitor Therapeutics Inc fundamental analysis
No fundamental analysis for Inhibitor Therapeutics Inc yet.
Inhibitor Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Inhibitor Therapeutics Inc
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies initially for basal cell carcinoma nevus syndrome (BCCNS) cancers by utilizing itraconazole; development of therapies initially for basal cell carcinoma (BCC) cancers; and SUBA-Itraconazole for the treatment of basal cell carcino…
Full company profileInhibitor Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Inhibitor Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -7.02M | -5.12M | -4.56M | -2.75M | -1.06M | -325K | -658K | -3.40M | -3.66M | -3.43M | -2.63M |
| EBITDA | - | - | - | - | - | -284K | 12.2M | -3.40M | -3.66M | -3.43M | -2.63M |
| Net Income | -7.00M | -5.10M | -4.55M | -2.73M | -1.06M | -299K | 12.1M | -3.03M | -3.34M | -3.30M | -2.60M |
| EPS | - | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.07 | -0.02 | -0.02 | -0.02 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 7.34M | 768K | 1.23M | 900K | 132K | 58.8K | 12.0M | 8.95M | 5.69M | 2.51M | 637K |
| Total Liabilities | 308K | 601K | 1.20M | 3.43M | 3.49M | 3.68M | 3.68M | 3.67M | 3.71M | 3.80M | 3.20M |
| Shareholders' Equity | 7.03M | 167K | 32.4K | -2.53M | -3.36M | -3.62M | 8.30M | 5.28M | 1.99M | -1.29M | -2.56M |
| Cash & Short-term Investments | 6.89M | 344K | 1.11M | 804K | 75.1K | 30.6K | 12.0M | 8.84M | 5.61M | 2.38M | 516K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.76M | -2.91M | -3.71M | -2.71M | -825K | -220K | 11.7M | -2.70M | -3.23M | -3.23M | -3.72M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -2.91M | -3.71M | -2.71M | -825K | -220K | 11.7M | -2.70M | -3.23M | -3.23M | -3.72M |
| Ratios | |||||||||||
| ROE | -99.6% | -3,062.6% | -14,065.2% | - | - | - | 145.9% | -57.3% | -168.2% | - | - |
| ROA | -95.4% | -664.2% | -369.0% | -303.7% | -802.9% | -508.0% | 101.1% | -33.8% | -58.6% | -131.4% | -408.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Inhibitor Therapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 99.2K | 0.00 | - |
| 2018 | USD 99.2K | 0.00 | - |
| 2017 | USD 99.2K | 0.00 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Inhibitor Therapeutics Inc
- Insiders 55.06%
- Institutions 0.00%
- Public & others 44.94%
- Shares outstanding 175M
- Free float 78.1M
Inhibitor Therapeutics Inc company profile
- Company name
- Inhibitor Therapeutics Inc
- Ticker
- INTI.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- 3014 West Palmira Avenue, Tampa, FL, United States, 33629-7264
- Phone
- 813 864 2562
- Website
- inhibitortx.com
About Inhibitor Therapeutics Inc
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies initially for basal cell carcinoma nevus syndrome (BCCNS) cancers by utilizing itraconazole; development of therapies initially for basal cell carcinoma (BCC) cancers; and SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. The company was founded in 1992 and is based in Tampa, Florida.
Inhibitor Therapeutics Inc management
2- Dr. Francis E. O'Donnell Jr., M.D.Founder, Executive Chairman & CEO · born 1950
- Mr. James A. McNulty CPAInterim CFO, Treasurer & Secretary · born 1950